Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users

Current HIV Research

Volumn 7, Issue 4, 2009, Pages 354-364

  Kresina, Thomas F ^a   Douglas, R Bruce ^b   McCance Katz, Elinore F ^c  

^a SAMHSA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti retroviral treatment; Buprenorphine; HIV AIDS; Methadone; Naltrexone; Substance abuse treatment

Indexed keywords

ABACAVIR; ACAMPROSATE; ALCOHOL; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; BUPRENORPHINE; COCAINE; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; DISULFIRAM; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; METHAMPHETAMINE; NALTREXONE; NEVIRAPINE; OPIATE; PLACEBO; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; AMENORRHEA; AREA UNDER THE CURVE; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; CONSTIPATION; DIAPHORESIS; DIRECTLY OBSERVED THERAPY; DISEASE ASSOCIATION; DRUG ABUSE; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EPIDEMIC; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; MEDICAL RESEARCH; OPIATE ADDICTION; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; POLYPHARMACY; PRESCRIPTION; PREVENTIVE HEALTH SERVICE; PSYCHOSOCIAL CARE; PUBLIC HEALTH PROBLEM; REVIEW; SEDATION; SEXUAL BEHAVIOR; SIDE EFFECT; SOCIAL DISCRIMINATION; STIGMA; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; ADDICTION; DRUG USE; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DRUG USERS; HUMANS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 69849110031     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209788680598     Document Type: Review

References (118)

1. Hendershot CS, Stoner SA, George WH, Norris J. Alcohol use, expectancies, and sexual sensation seeking as correlates of HIV risk behavior in heterosexual young adults. Psychol Addict Behav 2007; 21: 365-372 (Pubitemid 47488763)
2. World Health Organization. Alcohol use and sexual risk behaviours: a cross- culture study in eight countries. WHO Press Geneva Switzerland, ISBN 94 4 156289 7, 2005. available at : http://www.who.int/substance-abuse/publications/ alcohol-sexual-risk-crosscultural.pdf [Accessed 2/25/2009]
3. Hendershot CS, George WH. Alcohol and sexuality research in the AIDS era: trends in publication activity, target populations and research designs. AIDS Behav 2007; 11: 217-226
4. Kalichman SC, Simbayi LC, Kaufman M, Cain D, Jooste S. Alcohol use and sexual risk for HIV/AIDS in sub-Saharan Africa: Systemic review of empirical findings. Prev Sci 2007; 8: 141-151
5. Phorano OD, Nthomang K, Ntseane D. Alcohol abuse, genderbased violence and HIV/AIDS in Botswana: establishing the link based on empirical evidence. Sahara J 2005; 2: 188-202.
6. Simbayi LC, Kalichman SC, Cain D, Cherry C, Jooste S, Mathiti V. Alcohol and risk for HIV/AIDS among sexually transmitted infection clinic patients in Cape Town, South Africa. Subst Abus 2006; 27: 37-43.
7. Strebel A, Crawford T, Shefer A, et al. Social construction of gender roles, gender-based violence and HIV/AIDS in two communities of the Western Cape, South Africa. Sahara J 2006; 3: 516-528
8. Morojele NK, Brook JS, Kachieng'a MA. Perceptions of sexual risk behaviors and substance abuse among adolescents in South Africa: A qualitative investigation. AIDS Care 2006; 18: 215-219
9. Sawyer KM, Wechsberg WM, Myers BJ. Cultural similarities and differences between a sample of Black/African and colored women in South Africa: convergence of risk related to substance use, sexual behavior, and violence. Women Health 2006; 4: 73-92.
10. McCurdy SA, Williams ML, Kilonzo GP, Ross MW, Leshabari MT. Heroin and HIV risk in Dar es Salaam, Tanzania: youth hangouts, mageto and injecting practices. AIDS Care 2005; 17(Suppl 1): S65-76.
11. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STD 2008; 22: 233-243
12. Himelhoch S, Chander G, Fleishman JA, Hellinger J, Gaist P, Gebo KA. Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. Gen Hosp Psychiatry 2007; 29: 518-525 (Pubitemid 350088154)
13. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103: 1828-1836.
14. Alcohol and Drug Abuse Institute Library, University of Washington, Seattle available at: http://lib.adai.washington.edu/ instruments/ accessed 11/04/2008
15. Adams LL, Gatchel RJ, Robinson RC, et al. Development of a selfreport screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage 2004; 27: 440-459
16. Schlesinger CM, Ober C, McCarthy MM, Watson JD, Seinen A. The development and validation of the Indigenous Risk Impact Screen (IRIS): a 13-item screening instrument for alcohol and drug and mental health risk. Drug Alcohol Rev 2007; 26: 109-117
17. Miller PM, Thomas SE, Mallin R. Patient attitudes towards selfreport and biomarker alcohol screening by primary care physicians. Alcohol Alcohol 2006; 41: 306-310
18. Dalla-Dea HR, DeMicheli D, Formigoni ML. Effects of identification and usefulness of the Lie Scale of the Drug Use Screening Inventory (DUSI-R) in the assessment of adolescent drug use. Drug Alcohol Depend 2003; 72: 215-223
19. McCabe SE, Boyd CJ, Cranford JA, Morales M, Slayden J. A modified version of the Drug Abuse Screening Test among undergraduate students. J Subst Abuse Treat 2006; 31: 297-303. (Pubitemid 44425275)
20. Department of Health and Human Services (DHHS), Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - December 1, 2007 available at: http://www.aidsinfo. nih.gov/Guidelines/GuidelineDetail.aspx? MenuItem=Guidelines& Search=Off&GuidelineID=7&ClassID=1 accessed 11/17/2008
21. th ed. Text Revision American Psychiatric Association (publishers), Washington, DC 1994.
22. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use and psychiatric illness: Treatment issues and developing integrated models of care. J Urban Health 2004; 81: 719-734 (Pubitemid 39457952)
23. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin N Am 2007; 21: 149-179
24. Sorensen J, Copeland A. Drug abuse treatment as an HIV prevention strategy: A review. Drug Alcohol Depend 2000; 59: 17-31. (Pubitemid 30116835)
25. Substance Abuse and Mental Health Services Administration, (SAMHSA). Substance abuse treatment for persons with cooccurring disorders. Treatment Improvement Protocol (TIP) 42. DHHS Publication No. 05-3993. 2005 Rockville Maryland available at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5. chapter.740 73 [Accessed 02/26/2009]
26. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med 2000; 67: 347-364 (Pubitemid 30812062)
27. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-171. (Pubitemid 47207726)
28. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; 16: CD002207. (Pubitemid 351807246)
29. Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL. Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21: 193-195 (Pubitemid 43363679)
30. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/ naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008; 35: 87-92.
31. Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006; 31: 319-328
32. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005; 100: 150-158
33. Substance Abuse and Mental Health Services Administration, SAMHSA. Medication-assisted treatment for opioid addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) 43. DHHS Publication No. 05-4048. 2005 Rockville Maryland available at http://ncadistore.samhsa.gov/catalog/product Details.aspx?ProductID=17946 [Accessed 02/26/2009]
34. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New Engl J Med 2000; 343: 1290-1297
35. Farre M, Mas A, Torrens M, Moreno V, Camí J. Retention rate and illicit use during methadone maintenance interventions: a metaanalysis. Drug Alcohol Depend 2002; 65: 283-290 (Pubitemid 34159075)
36. Substance Abuse and Mental Health Services Administration, SAMHSA. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) 40. DHHS Publication No. 04-3939. 2004 Rockville Maryland available at http://ncadistore.samhsa.gov/ catalog/product Details.aspx?ProductID=16829 [Accessed 02/26/2009].
37. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. New Eng J Med 2002; 347: 817-823
38. Tallarida RJ, Cowan A. The affinity of morphine for its pharmacologic receptor in vivo. J Pharmacol Exp Ther 1982; 222: 198-201.
39. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995; 40: 27-35.
40. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2002; 2: CD001333.
41. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156: 1758-1764
42. Baros AM, Latham PK, Moak DH, Voronin K, Anton RF. What role does the measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 2007; 31: 596-603.
43. Greenstein RA, Evans BD, McLellan AT, O'Brian CP. Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend 1983; 12: 173-180
44. Jeffrey GP, Macquillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007; 45: 111-117 (Pubitemid 46144370)
45. Samet JH, Walley AY, Bridden C. Illicit drugs, alcohol and addiction in human immunodeficiency virus. Panminerva Med 2007; 49: 67-77.
46. Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol 2006; 26(Suppl 1): S37-42.
47. Ducharme LJ, Knudsen HK, Roman PM. Trends in the adoption of medications for alcohol dependence. J Clin Psychopharmacol 2006; 26(Suppl 1): S13-9.
48. Substance Abuse and Mental Health Services Administration, (SAMHSA). In. Incorporating Alcohol Pharmacotherapies into Medical Practice. Treatment Improvement Protocol (TIP). DHHS Publication No. 09-49. Rockville Maryland 2009 available at: http://ncadi.samhsa.gov/ accessed 02/26/2009
49. Suh JJ, Pettinati HM, Kampman KM, O'Brian CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006; 26: 290-302. (Pubitemid 43804621)
50. Fuller RK, Wiliford WO, Lee KK, Derman R. Veterans Administration cooperative study of disulfiram in the treatment of alcoholism: study design and methodological considerations. Control Clin Trials 1984; 5: 263-273 (Pubitemid 14005327)
51. Madan A, Parkinson A, Faiman MD. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 1998; 22: 1212-1219 (Pubitemid 28443143)
52. Barber TJ, Marett B, Waldron S, et al. Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice? AIDS 2007; 21: 1823-1824
53. O'Malley SS, Froehlich JC. Advances in the use of naltrexone: an integration of preclinical and clinical findings. Rec Dev Alcohol 2003; 16: 217-245
54. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 1996; 53: 250-257 (Pubitemid 26085207)
55. O'Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005; 162: 1423-1431
56. Patinati HM, Rabinowitz AR. Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep 2006; 8: 383-388
57. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction 1995; 90: 1179-1188
58. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002; 27: 596-606.
59. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001(Suppl 20); 62: 42-48 (Pubitemid 32917098)
60. Krupitsky EM, Zvartau EE, Lioznov DA, et al. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia. Eur Addict Res 2006; 12: 12-19
61. Jayaram-Lindstrom N, Hammarberg A, Beck O, Frank J. Naltrexone for the treatment of amphetamine dependence: A randomized, placebo-controlled trial. Am J Psychiatry 2008; 165: 1442-1448
62. McCann DJ. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clin Pharmacol Ther 2008; 83: 627-630
63. Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gammahydroxybutyrate, 1,4 butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 2008; 10: 69-74.
64. Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 2002; 31 (suppl 2): S62-9. (Pubitemid 35190560)
65. Theodore S, Cass WA, Nath A, Maragos WF. Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr HIV Res 2007; 5: 301-313 (Pubitemid 46785066)
66. Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Subst Abus 2008; 29: 31-49.
67. Person AK, Ramadhani HO, Thielman NM. Antiretroviral treatment strategies in resource-limited settings. Curr HIV/AIDS Res 2007; 4: 73-79 (Pubitemid 46806623)
68. Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, Cunningham CO. Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care STDS 2007(Suppl 1); 21: S68-76. (Pubitemid 46988398)
69. PEPFAR, The President's Emergency Plan for AIDS Relief. Latest Results. available at http://www.pepfar.gov/about/c19785.htm accessed 02/25/2009
70. PEPFAR, The President's Emergency Plan for AIDS Relief. Critical interventions in the focus countries: Treatment Chapter 2 In: The power of partnerships: The third annual report to congress on PEPFAR 2007 available at: http://www.pepfar.gov/pepfar/ press/81208.htm accessed 11/04/2008
71. World Health Organization. Basic principles for treatment and psychosocial support of drug dependent people living with HIV/AIDS. 2006 Available at: www.who.int/substance-abuse/publications/basic-principles-drug- hiv.pdf accessed 11/04/2008
72. Begre S, von Bardeleben U, Ladewig D, et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22: 211-215 (Pubitemid 34289398)
73. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 2003; 31: 742-747
74. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 435-443 (Pubitemid 28387767)
75. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001; 10: 296-307. (Pubitemid 34008323)
76. Rainey PM, Friedland GH, Snidow JW, et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am J Addict 2002; 11: 66-74.
77. Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000; 24: 241-248
78. Friedland G, Rainey P, Jatlow P, McCance-Katz EF. Pharmacokinetics (PK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy. In 14th International AIDS Conference; International AIDS Society: Barcelona, Spain 2002.
79. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13: 957-962
80. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33: 1595-1597 (Pubitemid 34246157)
81. Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 4148-4153 (Pubitemid 39434868)
82. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Brit J Clin Pharm 2001; 51: 213-217 (Pubitemid 32391497)
83. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 2000; 34: 405-407 (Pubitemid 30133611)
84. McCance-Katz EF, Rainey P, Friedland G, Jatlow P. The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003; 37: 476-482 (Pubitemid 37011769)
85. Package Insert. Aptivus (r), tipranavir.; Boehringer Ingelheim Pharmaceuticals, Inc.: Ridgefield, CT, 2005.
86. Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Exp Rev Clin Pharm 2008; 1: 115-127
87. Kreek MJ, Garfield JW, Gutjahr CL, Giusti M. Rifampin-induced methadone withdrawal. New Engl J Med 1976; 294: 1104-1106
88. Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998; 63: 655-662 (Pubitemid 28327893)
89. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Iummune Defic Syndr 2006; 41: 563-572
90. Bruce RD, McCance-Katz E, Karasch ED, Moody DE, Morse GD. Pharmacokinetic Interactions Between Buprenorphine and Antiretroviral Medications. Clin Infect Dis 2006; 43(Suppl 4): S216-23.
91. McCance-Katz E, Moody DE, Morse GD, et al. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clin Infect Dis 2006; 43(Suppl 4): S224-S34.
92. McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 2006; 43(Suppl 4): S235-46.
93. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 2006; 20: 783-784
94. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Dependence 2007; 91: 269-278
95. Kresina TF, Flexner CW, Sinclair J, et al. Alcohol Use and HIV Pharmacotherapy. AIDS Res Hum Retroviruses 2002; 18: 757-770
96. Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health 2007; 30: 5-13.
97. Flexner CW, Cargill V, Sinclair J, Kresina TF, Cheever L. Alcohol Use Can Result in Enhanced Drug Metabolism in HIV Pharmacotherapy. AIDS Patient Care STDS 2001; 15: 57-58 (Pubitemid 32164605)
98. McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44: 1686-1690
99. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39: 709-716
100. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Sub Use Misuse 2006; 41: 1395-1463 (Pubitemid 44472465)
101. Pineda JA, Macias J. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrobl Chemother 2005; 55: 417-419 (Pubitemid 40542577)
102. Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 2005; 46: 79-87.
103. Dresser G.K, Spence JD, Bailey DG. Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57. (Pubitemid 30055093)
104. Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharm 1999; 39: 1109-1125 (Pubitemid 30644013)
105. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2001; 40: 207-226 (Pubitemid 32324451)
106. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-291
107. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Safety 1998; 18: 83-97.
108. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005; 44: 1035-1050 (Pubitemid 41356390)
109. United States Federal Code, SEC. 3501. NOTE: 21 USC 801 Drug Abuse Treatment Act of 2000 (DATA 2000) available at http://buprenorphine.samhsa.gov/. /fulllaw.html [Accessed 11/04/ 2008].
110. Sullivan LE, Bruce RD, Haltiwanger D. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis 2006; 43(Suppl 4): S191-6. (Pubitemid 44901887)
111. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007; 18: 262-270 (Pubitemid 47126278)
112. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis 2004; 38 (Suppl): S376-87. (Pubitemid 38738534)
113. Lucas GM, Weidle PJ, Hader S, Morre RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis 2004; 38 (Suppl): S409-13. (Pubitemid 38738539)
114. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42: 1628-1635 (Pubitemid 43752653)
115. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Morre RD. Adherence, drug use, and treatment failure in a methadoneclinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STS 2007; 21: 564-574 (Pubitemid 350194958)
116. Wood E, Kerr T, Tyndall MW, Montaner JSC. A review of the barriers and facilitators of HIV treatment among injection drug users. AIDS 2008; 22: 1247-1256
117. World Health Organization "Antiretroviral Therapy for HIV infection in Adults and Adolescents: Recommendations for a Public Health Approach" 2006 revision. Available at: www.who.int/hiv/pub/guidelines/adult/en/index.html [Accessed 11/04/2008].
118. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26: 257-260 (Pubitemid 28182402)